ReviewBiochemistry and biophysics reports2025
Multiple roles of ANO6 in tumors, molecular mechanism and its potential therapeutic value.
Review in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Lipid flip-flop in biological membranes: through the lens of TMEM16F.Physiological reviews · 2026Review
- Machine learning-based programmed cell death gene signature for prognosis and drug sensitivity in breast cancer.Oncology letters · 2026Article
- LncRNA BMNCR Regulates Proliferation, Apoptosis and Inflammatory Response in Bovine Mammary Epithelial Cells Through the miR-145/ANO6 Axis.Animals : an open access journal from MDPI · 2026Article
- Recent advances in TMEM16F: structural plasticity, functional versatility, and implications for human diseases.Cell communication and signaling : CCS · 2026Review
- Special Issue "Ion Conductance and Ion Regulation in Human Health and Disease".International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anoctamin 6 (ANO6/TMEM16F) is a calcium-activated ion channel and phospholipid disruptor that plays a key role in maintaining cellular homeostasis. This review focuses on the role of ANO6 in various cancers. On one hand, ANO6 is highly expressed in pancreatic cancer, gastric cancer, and glioma, while its expression is downregulated in breast cancer, prostate cancer, cervical cancer, and ovarian cancer. This indicates its functional diversity across different cancer types, reflecting the complex regulatory mechanisms of ANO6 in the tumor microenvironment. In pancreatic cancer, ANO6 is highly expressed, and it promotes pancreatic cancer metastasis through the ERK signaling pathway. In melanoma, ANO6 is closely associated with poor patient prognosis, clinical-pathological characteristics, tumor immunity, and tumor heterogeneity. In breast cancer, ANO6 is a ferroptosis gene associated with prognosis, and its low expression is linked to poor outcomes, making it a key independent predictor of overall survival in breast cancer patients. Additionally, the relationship between ANO6 and immune cells highlights its potential role in cancer immune surveillance and therapy. Finally, we found that ANO6 may regulate immune cell exhaustion in the tumor microenvironment by influencing macrophage polarization and T cell recruitment and activation. This review highlights the diverse roles of ANO6 in different cancers and its potential as a diagnostic and therapeutic tool. Future studies should address the mechanistic details of ANO6 involvement in cancer, validate its clinical utility, and explore its therapeutic potential in combination with existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.